Viagra’s (Sildenafil) New Role: Hypertension to Erectile Dysfunction to Cancer

History:

Sildenafil, better known by its brand name, Viagra, has had an interesting journey since its inception. Originally developed to treat hypertension (high blood pressure), sildenafil became a blockbuster medication for erectile dysfunction (ED) after its unexpected success in improving blood flow. But now, this popular drug is being explored for a surprising new use: the treatment of cancer. This "repurposed, repurposed" medication is demonstrating powerful anti-cancer properties, giving new hope in the ongoing battle against cancer.

FDA Approval:

Sildenafil was first approved by the FDA in 1998 for the treatment of erectile dysfunction. It later gained approval for pulmonary arterial hypertension. While its application in cancer treatment is not yet FDA-approved, studies have shown promising results that are pushing this drug into the forefront of repurposed cancer therapies.

Original Indication:

Initially, sildenafil was designed to treat hypertension by dilating blood vessels. It was later repurposed for erectile dysfunction when clinical trials revealed its ability to increase blood flow, which was crucial for ED treatment.

Research to Repurpose for Cancer Treatment:

Researchers began investigating sildenafil's potential in oncology after discovering its ability to impact more than just blood flow. In cancer research, sildenafil has been found to inhibit cell proliferation, modulate the immune response, and prevent tumors from developing new blood vessels. These findings have opened the door for sildenafil to be repurposed yet again, this time for a potentially life-saving role in cancer treatment.

Preclinical Research:

Most of the knowledge regarding sildenafil's anti-cancer effects comes from preclinical studies. In these studies, scientists have explored sildenafil’s effects on various cancer types, focusing on its ability to stop cancer cell growth, induce programmed cell death (apoptosis), and disrupt tumor development. Animal models and cancer cell cultures have been pivotal in unveiling these promising outcomes.

Clinical Trials:

While clinical evidence is still emerging, there are ongoing trials evaluating sildenafil’s effectiveness in cancer patients, particularly in combination with existing chemotherapy regimens. Early clinical trials suggest that sildenafil could enhance chemotherapy's effects.

Mechanisms of Action: How Sildenafil Works Against Cancer

1. Inhibition of Phosphodiesterase Type 5 (PDE5):

Sildenafil’s primary mechanism of action is the inhibition of phosphodiesterase type 5 (PDE5), which increases levels of cyclic guanosine monophosphate (cGMP). This increase in cGMP is essential for inhibiting the proliferation of cancer cells and inducing apoptosis (programmed cell death). By halting cancer cell growth, sildenafil plays a critical role in controlling tumor progression.

2. Immune System Modulation:

Beyond its cardiovascular effects, sildenafil has shown the ability to modulate the immune system. It does this by decreasing the number of myeloid-derived suppressor cells (MDSCs). MDSCs are known to suppress the body’s immune response against tumors. By reducing these cells, sildenafil enhances the immune system’s ability to attack and destroy cancer cells, bolstering the body’s natural defenses against cancer.

3. Induction of Apoptosis:

Sildenafil showcases its direct cytotoxic potential by inducing apoptosis in cancer cells. This is achieved through the activation of protein kinase G (PKG), a protein involved in regulating the cell cycle. By inducing cell cycle arrest, sildenafil stops cancer cells from replicating and drives them towards programmed cell death, effectively reducing the tumor's size and growth potential.

4. Inhibition of Angiogenesis:

Tumors require a constant supply of nutrients to grow and metastasize, which they acquire through the formation of new blood vessels—a process called angiogenesis. Sildenafil inhibits this process by downregulating vascular endothelial growth factor (VEGF), a critical protein involved in blood vessel formation. By starving the tumor of essential nutrients, sildenafil helps slow down its growth and prevents the spread of cancer.

5. Synergistic Effects in Combination Therapy:

One of the most exciting aspects of sildenafil’s role in cancer treatment is its ability to enhance the effects of chemotherapeutic agents such as doxorubicin. Not only does sildenafil improve the penetration of these drugs into tumors, but it also makes cancer cells more sensitive to treatment, increasing the overall effectiveness of chemotherapy. This synergistic effect could potentially improve outcomes for cancer patients undergoing combination therapy.

Limitations and Future Directions

Limitations:

While preclinical research has demonstrated sildenafil’s anti-cancer potential, its use in cancer treatment is still in the early stages. Additionally, sildenafil’s original use for cardiovascular conditions may present some risks for patients with heart problems, so careful consideration must be given when using it for cancer.

What Does the Research Show?

Research has shown that sildenafil’s mechanisms—PDE5 inhibition, immune modulation, and inhibition of angiogenesis—are promising for cancer treatment. These effects, combined with the drug's ability to synergize with chemotherapy, suggest that sildenafil could be a powerful addition to the cancer treatment landscape. As more clinical trials are conducted, sildenafil’s full potential will likely be further uncovered.

Conclusion

Sildenafil, widely known for treating erectile dysfunction, has emerged as a potential cancer therapy due to its ability to inhibit cancer cell proliferation, induce apoptosis, modulate the immune system, and prevent angiogenesis. This versatile medication could become a valuable part of cancer treatment regimens, particularly when used in combination with chemotherapy. While much research remains to be done, sildenafil’s journey from hypertension to erectile dysfunction, and now to cancer, is a testament to the incredible possibilities of drug repurposing.

References

1. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12-21. doi:10.1016/ j.pharmthera.2014.11.005.

2. Serafini P, Meckel K, Kelso M, Noonan KA, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691-2702. doi:10.1084/ jem.20061104.

3. Tuttle TR, Mierzwa ML, Wells SI, Fox SR, Ben-Jonathan N, Callaghan MU, et al. Sildenafil enhances the cytotoxicity of doxorubicin in prostate cancer cells. J Cell Biochem. 2010;110(5):1220-1230. doi:10.1002/jcb.22643.

4. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 3’,5’-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60(13):3338-3342.

5. Das A, Durrant D, Koka S, Salloum FN, Xi L, Kukreja RC. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A. 2010;107(42):18202-18207. doi:10.1073/ pnas.1006775107.